25026-34-0

Basic information

• Product Name: 4-Chlorobenzeneacetyl chloride
• Synonyms: Benzeneacetyl chloride, 4-chloro-;4-Chlorophenylacetyl chloride, extra pure, 96%;(4-Chlorophenyl)acetic acid chloride;4-Chlorobenzeneacetic acid chloride;4-Chlorophenylacetic acid chloride;4-Chlorophenylacetyl chloride,96%;4-chlorophenylacethyl chloride;4-chlorophenyl chloride
• CAS NO: 25026-34-0
• Molecular Formula: C₈H₆Cl₂O
• Molecular Weight: 189.04
• EINECS: 246-571-1
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 25026-34-0.mol

Chemical Properties

• Boiling Point: 85 °C1 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Clear yellow to brown/Liquid
• Density: 1.292 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: n20/D 1.5510(lit.)
• Sensitive: Moisture Sensitive
• BRN: 637775
• CAS DataBase Reference: 4-Chlorobenzeneacetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chlorobenzeneacetyl chloride(25026-34-0)
• EPA Substance Registry System: 4-Chlorobenzeneacetyl chloride(25026-34-0)

Safety Data

• Hazard Codes: C
• Statements: 22-34-43
• Safety Statements: 26-36/37/39-45-24/25
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 25026-34-0(Hazardous Substances Data)

Usage

Chemical Properties

clear yellow to brown liquid

InChI:InChI=1/C8H6Cl2O/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4H,5H2

Upstream product

• 1878-66-6 4-chlorophenylacetic Acid 
• 79-37-8 oxalyl dichloride 
• 104-03-0 4-nitrobenzeneacetic acid 
• 74-11-3 para-chlorobenzoic acid 
• 122-01-0 4-chloro-benzoyl chloride 
• 3282-33-5 1-(4-chlorophenyl)-2-diazoethanone 
• 140-53-4 p-chlorobenzyl cyanide 
• 873-76-7 para-Chlorobenzyl alcohol 
• 622-95-7 4-chlorobenzyl bromide 

Downstream Products

• 19202-19-8 2-(4-chlorophenyl)-1-(pyrrolidin-1-yl)-ethanone 
• 99931-95-0 2-(4-chlorophenyl)-1-morpholinoethanone 
• 100623-07-2 (4-chloro-phenyl)-thioacetic acid S-phenyl ester 
• 51490-05-2 1,2-bis(4-chlorophenyl)ethanone 
• 109443-07-4 (4-chloro-phenyl)-thioacetic acid S-(4-chloro-phenyl ester) 
• 107028-33-1 1-(4-bromophenyl)-2-(4-chlorophenyl)ethanone 
• 62088-10-2 4-(4-chloro-phenyl)-3-oxobutyric acid ethyl ester 
• 101937-54-6 (4-chloro-phenyl)-acetic acid diallylamide 
• 100141-53-5 (4-chloro-phenyl)-acetic acid-(3-methoxy-propylamide) 
• 15485-64-0 2-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)ethan-1-one 
• 24091-92-7 methyl 2-bromo-2-(4-chlorophenyl)acetate 
• 33297-39-1 2-(4-chlorophenyl)-N,N-dimethylacetamide 
• 5292-72-8 2-(4-chlorophenyl)-N,N-diethylacetamide 
• 27396-18-5 tert.-Butyl-p-chlorphenylperacetat 

Relevant articles and documents

Synthesis and in vitro platelet aggregation and TP receptor binding studies on bicyclic 5,8-ethanooctahydroisoquinolines and 5,8-ethanotetrahydroisoquinolines

Eighteen novel bicyclic 1-substituted benzyl octahydro- and tetrahydroisoquinolines were synthesized and evaluated for human thromboxane A2/prostaglandin H2 (TP) receptor affinity and antagonism of TP receptor-mediated platelet aggre

Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity

Recent analyses have highlighted the promotion of cancer migration and invasion, mediated through HDAC via MMP-2 and MMP-9. Since both class 1 HDACs and MMP-2/9 are involved in the migration and invasion of cancer, an attempt has been taken to design dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping and molecular docking approaches. The designed molecules were synthesized and showed a range of inhibitory activity against different MMP subtypes. Most of these designed compounds were selective towards MMP-2 but less potent against anti-targets like MMP-8, -12, etc. The highly active MMP-2 inhibitors were also found to be active towards HDAC-8 but less potent against other class 1 HDACs (HDAC-1 and -2). Molecular dynamics simulations revealed that the designed compounds may be acting through a distinct mechanism of action in the 'acetate ion channel' of HDAC-8. Some potent dual MMP-2/HDAC-8 inhibitors were further explored for in vitro cellular assays against human lung carcinoma cell line A549. These analyses revealed that some of these dual inhibitors have considerable anti-migratory and anti-invasive properties. The work may help to obtain some useful dual inhibitors.

Design, Synthesis, and Biological Evaluation of Pyrazole Derivatives

In this in vitro study, a series of novel pyrazole derivatives were designed, synthesized, and evaluated against five human cancer cell lines (PC3, A549, HL60, HCT116, and SW620) for their antiproliferative and p53-MDM2 binding inhibitory activities. Although biological evaluations showed that this series of compounds possessed weak p53-MDM2 inhibitory activities, most of them displayed moderate to potent antiproliferative activities against the tested cells lines. Compound 11c exhibited the best potency for MDM2 (FP-IC50 = 29.22 μm) and demonstrated antiproliferative activities in response to the five tested cell lines (IC50 = 4.09-16.82 μm). Compared with the positive control Nutlin-1, there was enhanced antiproliferative activity to p53-mutated or p53-deficient cell lines (SW620, HL60, and PC3).

Synthesis and peripheral substituent effects of bay-annulated indigo derivatives

In this study, indolo-naphthyridine-6,13-diones (5a–d) with four different peripheral substituents were prepared via bay-annulation reactions of indigo. The resulting compounds (5a–d) exhibited fluorescence in the red to near-IR region, while the parent indigo molecule showed no fluorescence. Although the peripheral substituents were oriented to the exterior of the π-conjugated system, the electronic structure affected the absorption and fluorescence spectra. Moreover, calculated molecular orbitals and absorption spectra successfully reproduced the experimental absorption spectra and cyclic voltammograms.

Synthesis, Characterization and Antimicrobial Activity of N-2-(4-Chlorophenyl)acetyl Derivatives of (S)-Amino Acids

This paper reports the synthesis, characterization and antibacterial activity of N-2-(4-chlorophenyl)acetyl derivatives of various (S)-amino acids such as (S)-alanine, (S)-phenylalanine, (S)-leucine, (S)-methionine, (S)-proline and (S)-tryptophane. These

Synthesis and in vitro anti-platelet aggregation activities of 2-methoxy-5-arylamido-N-(pyridin-3-yl-methyl)benzamides

In order to discover novel compounds with anti-platelet aggregation activities, a series of novel 2-methoxy-5-arylamido-N-(pyridin-3-ylmethyl)benzamides (1a–n) were synthesized and their anti-platelet aggregation activities were evaluated by the turbidimetric method in response to the following agonists: adenosine diphosphate (ADP) (5 mM/L), arachidonic acid (AA) (20 μM/L), and collagen (1 mg/mL). Those synthesized compounds that have better in vitro activities were subjected to cell toxicity tests via cell counting kit-8 (CCK-8) assay. The biological evaluation revealed that compound 1a (IC50: 0.21 μM/L) exhibited the highest anti-platelet aggregation activities when ADP was selected as an inducer, and compound 1b (IC50: 0.23 μM/L) showed the best activities when AA was selected as inducer, and compound 1m (inhibition rate: 55.06%) had significant anti-platelet aggregation activities when collagen was selected as inducer among all target compounds. Moreover, the effect of cell toxicity exhibited that none of the compounds had obvious cell toxicity against L929 cells. Therefore, 2-methoxy-5-arylamido-N-(pyridin-3-ylmethyl)benzamides have the potential to become a novel kind of anti-platelet drugs and deserve further study.

Preparation of Organic Nitrates from Aryldiazoacetates and Fe(NO3)3·9H2O

A thermal protocol is reported for the formal insertion of nitric acid into aryldiazoacetates using Fe(NO3)3·9H2O. This strategy is mild and high yielding and allows the preparation of a large variety of members of an unprecedented family of organic nitrates. The nitrate group can be also readily transformed into other functional groups and heterocyclic moieties and can possibly allow new biological explorations of untapped potential associated with their NO-releasing ability.

Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage

Preventing filoviruses in the entry stage is an attractive antiviral strategy. Taking aloperine, a Chinese natural herb with an endocyclic skeleton, as the lead, 23 new aloperine derivatives were synthesized and evaluated for their anti-filovirus activiti

Imidazopyrazinones (IPYs): Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones

In our quest for new antibiotics able to address the growing threat of multidrug resistant infections caused by Gram-negative bacteria, we have investigated an unprecedented series of non-quinolone bacterial topoisomerase inhibitors from the Sanofi patrim

Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors

In this study, two series of novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives containing an α,β-unsaturated lactone fragment were synthesized and screened for Topo I inhibition and antitumor activity. The topoisomerase I inhibitory activities and cytotoxicities against three human cancer cell lines (MCF-7,Hela,A549) were evaluated. The results revealed that series 2, compounds bearing an exocyclic double bond on the furanone ring, generally showed more potent activity than series 1, compounds lacking an exocyclic double bond. Several compounds of series 2 possess significant Topo I inhibitory activity and potent antiproliferative activity against cancer cell lines. Further mechanism studies of the most active compound of series 2 (B-15) indicated that synthetic compounds can not only stabilize the drug-enzyme-DNA covalent ternary complex as well as camptothecin, but also interfere with the binding between Topo I and DNA. The binding patterns of these compounds with Topo I and structure-activity relationships are discussed.